A proposed change to Medicare’s reimbursement of hearing aids could leave patients on their own when they need the a specific type of bone-anchored hearing aid implant, according to device maker Cochlear Ltd. (ASX:COH).
UPDATED March 21, 2013 with comments from Cochlear Americas president, principal investigator.
Sorin Group (BIT:SRN) managed to raise its bottom line despite flat sales for 2011 by raising its gross margin via restructuring, posting a profit increase of 48.3% for the year.
The Milanese cardiovascular device maker reported profits of $75.2 million (~€58.0 million) on sales of $963.4 million (~€743.4 million), compared with profits of $50.7 million (~€39.1 million) on sales of $966.5 million (~€745.8 million) during 2010.
Say hello to MassDevice +3, a bite-sized view of the top three med-tech stories of the day. This latest feature of MassDevice.com’s coverage highlights our three biggest and most influential stories from the day’s news to make sure you’re up to date on the headlines that continue to shape the medical device industry.
If you read nothing else today, make sure you’re still in the know with Massdevice +3.
Australian-based Cochlear Ltd. (ASX:COH), the world’s biggest maker of bionic ears, saw stocks drop by nearly 20 percent after a voluntary recall of its popular titanium hearing implants.
Cochlear recalled its Nucleus CI500 range of implants from shelves after an unexplained increase in failures in its CI512 implant model.